Glycobiarsol
|
WikiDoc Resources for Glycobiarsol |
|
Articles |
|---|
|
Most recent articles on Glycobiarsol Most cited articles on Glycobiarsol |
|
Media |
|
Powerpoint slides on Glycobiarsol |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Glycobiarsol at Clinical Trials.gov Clinical Trials on Glycobiarsol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Glycobiarsol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Glycobiarsol Discussion groups on Glycobiarsol Patient Handouts on Glycobiarsol Directions to Hospitals Treating Glycobiarsol Risk calculators and risk factors for Glycobiarsol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Glycobiarsol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Glycobiarsol (trade name Milibis) is an antiprotozoal agent that has been used in humans[1] as well as in dogs.[2]
References
- ↑ PMID 13214428 (PMID 13214428)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 5389346 (PMID 5389346)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand